周金英,王莹,颜红兵

• 1:国家心血管病学中心北京协和医学院中国医学科学院阜外医院冠心病中心100037北京
• 2:国家心血管病学中心中国医学科学院阜外医院深圳医院冠心病中心

摘要(Abstract)：

<正>2020年3月底在美国心脏病学会2020年会上公布的3项替格瑞洛单药治疗的研究结果显示,在急性冠状动脉综合征(acute coronary syndrome, ACS)接受经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)的患者[1]、复杂PCI患者[2]和合并糖尿病PCI患者中[3],应用替格瑞洛单药治疗获益。毫无疑问,这3项研究为改变目前的临床实践和指南提供了更多的循证医学证据。

关键词(KeyWords)： 替格瑞洛;阿司匹林;经皮冠状动脉介入治疗;急性冠状动脉综合征

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周金英,王莹,颜红兵

参考文献(References)：

• [1]Jang Y.Ticagrelor with or without aspirin in acute coronary syndrome after PCI:randomized evaluation of ticagrelor monotherapy after3-month dual antiplatelet therapy in acute coronary syndrome(the TICO trial).Presented on:March 30,2020.ACC 2020
• [2]Dangas G,Baber U,Sharma S,et al.Ticagrelor with aspirin or alone after complex PCI:the TWILIGHT-COMPLEX analysis.JAm Coll Cardiol,2020.[Epub ahead of print]
• [3]Angiolillo DJ,Baber U,Sartori S,et al.Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention.J Am Coll Cardiol,2020.[Epub ahead of print]
• [4]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol,2016,68(10):1082-1115.
• [5]Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for CardioThoracic Surgery(EACTS).Eur Heart J,2018,39(3):213-260.
• [6]Vane JR,Botting RM.The mechanism of action of aspirin.Thromb Resh,2003,110(5-6):255-258.
• [7]Yusuf S,Zhao F,Mehta SR,et al.Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.Eff ects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.N Engl J Med,2001,345(7):494-502.
• [8]O'Brien CW,Juraschek SP,Wee CC.Prevalence of aspirin use for primary prevention of cardiovascular disease in the United States:Results from the 2017 National Health Interview Survey.Ann Intern Med,2019.[Epub ahead of print]
• [9]Derry S,Loke YK.Risk of gastrointestinal haemorrhage with long term use of aspirin:meta-analysis.BMJ,2000,321(7270):1183-1187.
• [10]Nikolsky E,Stone GW,Kirtane AJ,et al.Gastrointestinal bleeding in patients with acute coronary syndromes:incidence,predictors,and clinical implications:analysis f rom the ACUITY(Acute Catheterization and Urgent Intervention Triage Strategy)trial.J Am Coll Cardiol,2009,54(14):1293-1302.
• [11]Pratt S,Thompson VJ,Elkin EP,et al.The impact of upper gastrointestinal symptoms on nonadherence to,and discontinuation of,low-dose acetylsalicylic acid in patients with cardiovascular risk.Am J Cardiovasc Drugs,2010,10(5):281-288.
• [12]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371(23):2155-2166.
• [13]Dobesh PP,Oestreich JH.Ticagrelor:pharmacokinetics,pharmacodynamics,clinical effi cacy,and safety.Pharmacotherapy,2014,34(10):1077-1090.
• [14]Teng R,Maya J,Butler K.Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.Platelets,2013,24(8):615-624.
• [15]Baber U,Zafar MU,George Dangas G,et al.Ticagrelor with or without aspirin after PCI:The TWILIGHT Platelet Substudy.J Am Coll Cardiol,2020,75(6):578-586.
• [16]Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomised double-blind study.Lancet,2010,375(9711):283-293.
• [17]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361(11):1045-1057.
• [18]Vranckx P,Valgimigli M,Jüni P,et al.Ticagrelor plus aspirin for1 month,followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,followed by aspirin monotherapy for 12 months after implantation of a drugeluting stent:a multicentre,open-label,randomised superiority trial.Lancet,2018,392(10151):940-949.
• [19]Franzone A,Mc Fadden E,Leonardi S,et al.Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting.J Am Coll Cardiol,2019,74(18):2223-2234.
• [20]Mehran R,Baber U,Sharma SK,et al.Ticagrelor with or without aspirin in high-risk patients after PCI.N Engl J Med,2019,381(21):2032-2042.
• [21]Baber U.Ticagrelor with aspirin or alone in high-risk patients after coronary intervention for acute coronary syndrome.Presented at:AHA 2019.November 17,2019.Philadelphia,PA.
• [22]Kim C,Hong SJ,Shin DH,et al.Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents:TICO trial rationale and design.Am Heart J,2019,212:45-52.